Ankylosing spondylitis (NICE TA383)
Infliximab is recommended, within its marketing authorisations, as an option for treating severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non‑steroidal anti‑inflammatory drugs. Infliximab is recommended only if treatment is started with the least expensive infliximab product. People currently receiving infliximab should be able to continue treatment with the same infliximab product until they and their NHS clinician consider it appropriate to stop.
Reason for decision: